Retraction Note: LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration

Wang, Qinganzi; Yang, Yongxiu; Liang, Xiaolei

doi:10.1186/s13048-020-00754-0

Cited by 5 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTEN can dephosphorylate PIP3 and maintain PIP3 at a low level, thereby down-regulating the PI3K/AKT pathway ( Carnero et al, 2008 ). Studies have shown that mutation or deletion of PTEN can increase the proliferation, migration, invasion and cisplatin resistance of endometrial cancer cells ( Chen et al, 2018 ; Wang et al, 2020 ). PTEN is the most frequently mutated gene in endometrial cancer and has the highest mutation rate in endometrioid adenocarcinomas, but mutations in serous carcinomas are very rare.…”

Section: Discussionmentioning

confidence: 99%

LncRNAs signatures associated with cuproptosis predict the prognosis of endometrial cancer

Feng

2023

Front. Genet.

View full text Add to dashboard Cite

Background: Endometrial cancer (UCEC) is the sixth most common cancer in women, and although surgery can provide a good prognosis for early-stage patients, the 5-year overall survival rate for women with metastatic disease is as low as 16%. Long non-coding RNAs (LncRNAs) are thought to play an important role in tumor progression. Cuproptosis is a recently discovered form of cell death in which copper binds directly to the lipoacylated component of the tricarboxylic acid (TCA) cycle. The aggregation of these copper-bound listed mitochondrial proteins and the loss of Fe-S cluster proteins trigger proteotoxic stress, which leads to cell death. Therefore, the aim of this work was to investigate the role of Cuproptosis-related LncRNAs signaling in clinical prognostic prediction and immunotherapy, as well as the relationship between tumor mutation burden.Methods: Genomic, clinical and mutational data of endometrial cancer patients were presented in the TCGA database, and cuproptosis-related genes obtained from related studies. Coexpression analysis and Cox regression analysis were used to construct prognostic features. Patients were divided into high risk group and low risk group, and then ROC, survival rate, risk curve, principal component analysis, independent prognostic analysis and clinical subgroup model validation were performed to observe the prognostic value of characteristics. Subsequently, the GO and genomic KEGG enrichment and immune-related functions of LncRNAs as well as the tumor mutation burden were analyzed.Results: In 548 UCEC case data, we identified five associated LncRNAs co-expressed with cuproptosis genes, and we found that high-risk patients had poorer overall survival (OS), progression-free survival (PFS), and higher mortality. Independent prognostic analysis, ROC showed that the LncRNAs associated with cuproptosis could accurately predict the prognosis of patients. Enrichment analysis revealed that the biological functions of LncRNAs were related to tumorigenesis. We also discovered suppression of immune-related functions in high-risk patients with oncogene mutations, higher tumor mutation burden in low-risk patients, and longer overall survival in patients with higher tumor mutation burden.Conclusion: The identification of five LncRNAs associated with cuproptosis can accurately predict the prognosis of patients with endometrial cancer, and may provide a new perspective for clinical application and immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

LncRNAs signatures associated with cuproptosis predict the prognosis of endometrial cancer

Feng

2023

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…PTEN mutation is the most frequent type of mutation in EC [13]. Tumor suppressor PTEN has been shown to interact with cell adhesion complexes and stabilize cell junctions, thereby reducing invasion and metastasis of a range of cancer cells including EC [14][15][16]. Previous studies have been keen to investigate the in uence of PTEN mutation on the progression and prognosis of endometrial cancer, but few focused on the development of PTEN mutational status associated prognostic signature [17][18][19].…”

Section: Discussionmentioning

confidence: 99%

Significance of PTEN Mutational Status Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma

Wang

Liu

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundPTEN mutation had been reported to be involved in the development and prognosis of endometrial carcinoma (EC). However, a prognostic genes signature associated with PTEN mutational status has not been developed. In this study, we aim to conduct a PTEN mutation associated prognostic genes signature for EC.MethodsWe obtained the simple nucleotide variation and transcriptome profiling data from The Cancer Genome Atlas database as training data. Lasso Cox regression algorithm was used to establish PTEN mutation associated prognostic genes signature. The overall survival rate of the high-risk and low-risk groups was determined by Kaplan-Meier (K-M) method. The accuracy of risk score prediction was tested by ROC curve.ResultsK-M curves revealed that the EC patients with PTEN mutation have favorable survival outcome. Differential expression analysis between the EC patients with PTEN mutation and PTEN wild identified 224 differential expression genes (DEGs). Eighty-four DEGs with prognostic value was fitted into least absolute shrinkage and selection operator (LASSO)–Cox analysis and a seven PTEN mutation associated prognostic genes signature with robust prognostic ability was constructed, which was successfully validated in the other two datasets from cBioPortal database as well as 60 clinical specimens. Furthermore, the PTEN mutation associated prognostic genes signature had been proved to be an independent prognostic predictor for EC. Remarkably, the EC patients in high-risk group were characterized with higher stages and grades as well as lower tumor mutation burden of EC, with poor survival outcome. Collectively, the PTEN mutation associated prognostic genes signature was a favorable prognostic biomarker for EC.ConclusionIn summary, we conducted and validated a prognostic predictor for EC associated with PTEN mutational status, which may be used as favorable prognostic biomarkers and therapeutic targets for EC.

show abstract

PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role

Roshandel

Noorazar

Farhadihosseinabadi

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Hematopoietic cancers are among the most common malignancies worldwide, which are divided into different types depending on the origin of tumor cells. In recent years, the pivotal role of different signaling pathways in the onset and progression of these cancer types has been well established. One of these pathways, whose role in blood malignancies has been well-defined, is PI3K/mTOR/AKT axis. The signaling pathway involves in a wide variety of important biological events in cells. It is clear that dysregulation of mediators involved in PI3 kinase signaling takes a pivotal role in cancer development. Considering the undeniable role of miRNAs, as one of the well-known families of non-coding RNAs, in gene regulation, we aimed to review the role of miR-NAs in regulation of PI3 kinase signaling effectors in hematopoietic cancers.

show abstract

Retraction Note: LncRNA CTBP1-AS2 sponges miR-216a to upregulate PTEN and suppress endometrial cancer cell invasion and migration

Abstract: This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13048-020-00754-0.

Cited by 5 publications

References 1 publication

LncRNAs signatures associated with cuproptosis predict the prognosis of endometrial cancer

LncRNAs signatures associated with cuproptosis predict the prognosis of endometrial cancer

Significance of PTEN Mutational Status Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma

PI3 kinase signaling pathway in hematopoietic cancers: A glance in miRNA's role

Contact Info

Product

Resources

About